Your search for major depressive disorder returned 64 results

Patients with MDD were randomly assigned in a 1:1:1 ratio to receive 1.5 mg daily cariprazine, 3.0 mg daily cariprazine, or placebo for 6 weeks.

Investigators sought to evaluate the association of comorbid PD and SUD with the probability of hospitalization among patients with COVID-19 in the emergency department.

Investigators searched publication databases for randomized controlled trials evaluating cognitive training and remediation interventions among patients with MDD.

Seventeen samples from 13 countries were evaluated for associations between brain structural changes observed by MRI and BMI among patients with bipolar disorder and healthy controls.

Investigators designed this study to evaluate the feasibility and potential utility of a peer-led CBT-based workshop for PPD.

Patients who had treatment-naïve MDD were recruited in the US between 2007 and 2013 for the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study.

Investigators sought to characterize psychotropic drugs used to treat patients with bipolar disorder and assess changes in medication treatments in acute and maintenance episodes, and overall adherence.

Researchers seek to evaluate whether trauma-focused therapy adjunctive to treatment as usual (TAU) leads to a greater reduction of depressive symptoms posttreatment vs TAU exclusively in patients with major depressive disorder with childhood trauma.

The Alpha-Stim-D trial was a noncommercial, multicenter, randomly assigned, parallel group, double-blind trial conducted at 25 primary care practices in the United Kingdom.

Investigators from Texas Tech University searched publication databases for studies evaluating risk for diabetes mellitus, hypertension, dyslipidemia, and atherosclerotic macrovascular disease in the setting of ASD.

Investigators sought to assess associations for US Army soldiers bullied by fellow soldiers with mental health outcomes.

Investigators sourced data for this study from the Stockholm Major Depressive Disorder Cohort. Between 2010 and 2018, all patients in the Stockholm region who met the criteria for MDD were enrolled in the cohort.

Investigators searched publication databases for studies that evaluated the association between childhood maltreatment and mental health outcomes.

The REAL-ESK study was an observational, retrospective, multicenter study conducted in Italy.

Children and adolescents were evaluated for receipt of antipsychotics between 2000 and 2019 in England.

Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.

Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.

Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.

Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.

The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.

Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.

Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.

Electronic health records from 77 health care organizations in the US were evaluated for a risk for endocarditis among patients with opioid use disorder or cocaine use disorder on the basis of contracting COVID-19.

For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.

The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.

This prospective, multi-center, open-label trial, CAN-BIND-1 was conducted between 2012 and 2017.

Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.

Researchers explored the neurobiology related to reward-based reinforcement learning and psychomotor retardation in patients in remission from MDD.

Researchers examined correlations between suicidal ideation and suicide attempt history in patients with treatment-resistant depression following ketamine infusion.

To learn more about the impact of depression therapy on anxiety symptoms, researchers conducted a randomized controlled clinical trial with teenagers to compare the results of personalized depression therapy to a program that does not match their risk factors.